Prognosis of lung cancer associated with cystic airspaces: A propensity score matching analysis

医学 肺癌 内科学 匹配(统计) 倾向得分匹配 癌症 病理 肿瘤科
作者
Yingran Shen,Yunfei Zhang,Yanhua Guo,Weitong Li,Yan Huang,Tong Wu,Gening Jiang,Jie Dai
出处
期刊:Lung Cancer [Elsevier]
卷期号:159: 111-116 被引量:23
标识
DOI:10.1016/j.lungcan.2021.07.003
摘要

The association between the morphological characteristics and survival outcome of lung cancer associated with cystic airspaces (LCCAs) is unclear due to rarity of this disease. The current study attempted to compare the survival outcome between LCCAs and non-LCCAs and investigate the correlation between imaging features and prognosis of LCCA.Of 10,835 patients diagnosed with non-small cell lung carcinoma (NSCLC) between January 2015 and December 2016, 123 patients with LCCA were included. The non-LCCA group comprised 3136 patients with primary solitary adenocarcinoma or squamous cell lung cancer. Propensity score matching (PSM) was performed for age, sex, tumor size, tumor stage, and lymph node involvement in a 1:1 ratio between the LCCAs and non-LCCAs, and the correlation between radiological features and recurrence-free survival (RFS) was analyzed.The computed tomography (CT) lesion size was found to be higher in all LCCA subtypes, particularly in Type III (a cystic airspace with a mural nodule) and Type IV (mixed) LCCAs (3.09 and 3.65 cm, respectively), than in non-LCCAs (2 cm) after PSM. Three-year RFS in the LCCA group was higher than in the non-LCCA group (Type I- IV LCCAs: 100%, 84%, 77% and 83%, respectively vs. non-LCCAs: 77%). However, statistically significant difference was only found in comparison between LCCA Type I (thin-walled) and non-LCCA groups (P = 0.026). Type III lung cancer exhibited the worst survival among all four LCCA subtypes.The CT lesion size and pathologic tumor size varied significantly across LCCAs. Type I LCCAs exhibited better survival than non-LCCAs, whereas Type III LCCAs exhibited the worst survival rate among the four LCCA subtypes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
3秒前
LLLK发布了新的文献求助10
4秒前
123发布了新的文献求助10
4秒前
5秒前
5秒前
ee应助科研通管家采纳,获得10
5秒前
所所应助科研通管家采纳,获得10
5秒前
5秒前
ee应助科研通管家采纳,获得10
6秒前
上官若男应助科研通管家采纳,获得10
6秒前
大模型应助科研通管家采纳,获得10
6秒前
6秒前
Orange应助科研通管家采纳,获得10
6秒前
ee应助科研通管家采纳,获得10
6秒前
顾矜应助lin采纳,获得10
6秒前
6秒前
块块的加隆满口袋完成签到,获得积分10
6秒前
ee应助科研通管家采纳,获得10
6秒前
6秒前
Criminology34应助科研通管家采纳,获得10
6秒前
ee应助科研通管家采纳,获得10
6秒前
我是老大应助科研通管家采纳,获得10
6秒前
6秒前
fengl发布了新的文献求助10
7秒前
惜肉龟完成签到,获得积分10
9秒前
CipherSage应助旦皋采纳,获得10
9秒前
酷波er应助旦皋采纳,获得10
9秒前
无花果应助旦皋采纳,获得10
9秒前
科研通AI6.3应助旦皋采纳,获得10
9秒前
SciGPT应助旦皋采纳,获得10
9秒前
9秒前
今后应助旦皋采纳,获得10
9秒前
科研通AI6.1应助旦皋采纳,获得10
9秒前
科研通AI6.2应助旦皋采纳,获得10
9秒前
longuy完成签到,获得积分10
9秒前
深情安青应助旦皋采纳,获得30
9秒前
科研通AI6.3应助旦皋采纳,获得10
9秒前
颦颦完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Handbook of pharmaceutical excipients, Ninth edition 5000
Aerospace Standards Index - 2026 ASIN2026 2000
Digital Twins of Advanced Materials Processing 2000
Social Cognition: Understanding People and Events 1200
Polymorphism and polytypism in crystals 1000
Signals, Systems, and Signal Processing 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6036841
求助须知:如何正确求助?哪些是违规求助? 7756755
关于积分的说明 16215982
捐赠科研通 5182881
什么是DOI,文献DOI怎么找? 2773678
邀请新用户注册赠送积分活动 1756929
关于科研通互助平台的介绍 1641299